
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona demonstrated noteworthy financial growth, with reported sales in Europe increasing by 9.9% and 2.6% on a constant currency basis, indicating strong market performance. The company's Wellspect Healthcare segment was a standout performer, generating $83 million in revenue, representing a 15.6% increase reported and a consistent growth trajectory across all sales regions. Additionally, expectations for improving operating expenses as a percentage of revenue suggest ongoing efficiency gains, positioning Dentsply Sirona favorably for future performance.
Bears say
Dentsply Sirona has revised its sales expectations downwards, now anticipating a constant currency sales decline of 4% to 5%, a notable shift from its previous forecast of 2% to 4%. The company is also facing pressure on its gross margin, projecting a 160 basis point decline in GAAP gross margin in Q3 2025 compared to Q3 2024, alongside a decrease in adjusted EBITDA margin expectations for FY 2025, now estimated to be greater than 18%. Significant challenges are highlighted in the orthodontics segment, specifically a 15% decline attributed to issues related to the Byte business, which is expected to contribute to reduced earnings per share, now modeled at $1.60 down from $1.85.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares